Company: PSTV
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001193125-25-073481
Chunk: 25

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-04
Form: S-3
Chunk 25
---
 liabilities under the Securities Act.

12

We agreed to keep this prospectus effective until the earlier of (i) the date that such shares of
common stock become eligible for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 and certain other
conditions have been satisfied, or (ii) all of the shares of common stock have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect.

There can be no assurance that any selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement of
which this prospectus forms a part.

Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale
securities may not simultaneously engage in market-making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling
stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the selling stockholders or any
other person. Regulation M may also restrict the ability of any person engaged in the distribution of the shares of common stock to engage in market-making activities with respect to the shares of common stock. All of the foregoing may affect the
marketability of the shares of common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock.

13

LEGAL MATTERS Hogan Lovells US LLP, Houston, Texas, will pass upon the validity of the shares of our common stock offered by this prospectus. EXPERTS The consolidated financial statements of Plus Therapeutics, Inc. as of December 31, 2024 and 2023 and for the years then ended incorporated by reference in this prospectus and in the Registration Statement have been so incorporated in reliance on the report of BDO USA, P.C., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. WHERE YOU CAN FIND ADDITIONAL INFORMATION This prospectus is part of the registration statement on Form S-3that we filed with the SEC under the Securities Act and does not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in